Xiamen University team: It is expected to develop a vaccine to prevent 200 kinds of HPV

Science and Technology Daily (Reporter Xie Kaifei correspondent Ouyang Guilian) the third generation of cervical cancer vaccine research has made new progress. Reporters recently learned from Xiamen University National Infectious Disease Diagnostic Reagents and Vaccine Engineering Technology Research Center, the center Xia Ningyi, Li Shaowei team invented a new hybrid assembly technology, built a variety of other types of papillomavirus (hereinafter referred to as HPV) at the same time to produce protective effects of the "hybrid virus-like particles", combined with the team's early design of three types of embedded particle technology, is expected to develop a new multi-price HPV vaccine to prevent more than 200 types of HPV. The findings were published recently in the international journal Nature Communications.
cancer is one of the three most common malignant tumors in women, which seriously threatens women's health. Almost all cervical cancers are associated with a certain type of HPV infection. At present, more than 200 types of HPV have been identified, of which at least 25 types are associated with or may be related to the occurrence of cervical, vaginal, vulvixic, etc.
HPV vaccine is an effective means of preventing HPV-related diseases such as cervical cancer. Currently, vaccines on the market include HPV prices, four prices and nine prices. Both the two-price vaccine and the four-price vaccine can only prevent about 70% of cervical cancer, while the nine-price vaccine can only prevent about 90% of cervical cancer. Therefore, it is necessary to develop a broader range of cervical cancer vaccines. However, the existing first- and second-generation cervical cancer vaccines use "viral-like particles" similar to HPV natural virus particles as vaccine immunogens. If a new generation of cervical cancer vaccine is developed in the traditional way, it will face problems such as high vaccination dose, large potential side effect and difficult production process.
On the basis of pioneering the third generation cervical cancer vaccine development technology, the researchers continued to design a new type of "hybrid virus-like particles" based on their in-depth understanding of the mechanism of virus-like particle assembly of HPV, and verified it by means of frozen electron mirror analysis particle morphology, monoclonal antibody analysis of particle antigen.
" research provides a key technical basis for the development of a new generation of multi-priced cervical cancer vaccines covering a broader spectrum of all high-risk types of HPV, and provides new ideas for the design of vaccines for other highly mutated virus vaccines and new antigens targeting tumors. Li Shaowei said.